Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.6 SEK | -0.34% | +6.28% | -43.08% |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 155M 14.16M | Sales 2025 * | 238M 21.81M | Capitalization | 1.94B 177M |
---|---|---|---|---|---|
Net income 2024 * | 37M 3.39M | Net income 2025 * | 37M 3.39M | EV / Sales 2024 * | 11.7 x |
Net cash position 2024 * | 120M 10.97M | Net cash position 2025 * | 93M 8.51M | EV / Sales 2025 * | 7.74 x |
P/E ratio 2024 * |
51.6
x | P/E ratio 2025 * |
22.5
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
1 day | -0.34% | ||
1 week | +6.28% | ||
Current month | +6.28% | ||
1 month | -13.95% | ||
3 months | -37.02% | ||
6 months | -38.97% | ||
Current year | -43.08% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 29.6 | -0.34% | 17,178 |
24-05-07 | 29.7 | -2.62% | 178,820 |
24-05-06 | 30.5 | +4.99% | 225,219 |
24-05-03 | 29.05 | +1.93% | 30,962 |
24-05-02 | 28.5 | +2.33% | 32,687 |
Delayed Quote Nasdaq Stockholm, May 08, 2024 at 06:52 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.08% | 178M | |
-1.59% | 12.58B | |
+0.13% | 8.51B | |
-1.20% | 5.29B | |
+20.18% | 5.16B | |
-0.74% | 4.55B | |
-54.68% | 3.04B | |
+24.56% | 3B | |
+25.13% | 2.17B | |
-1.86% | 1.92B |
- Stock Market
- Equities
- GENO Stock